ONC
BeiGene, Ltd. American Depositary SharesONC
ONC
About: Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Employees: 11,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $22.6M
10% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 31
4% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 75
0% more funds holding
Funds holding: 223 [Q3] → 223 (+0) [Q4]
0.22% less ownership
Funds ownership: 3.72% [Q3] → 3.49% (-0.22%) [Q4]
23% less capital invested
Capital invested by funds: $10.4B [Q3] → $8.06B (-$2.35B) [Q4]
40% less funds holding in top 10
Funds holding in top 10: 10 [Q3] → 6 (-4) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$312
20%
upside
Avg. target
$323
24%
upside
High target
$348
34%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Gregory Renza 29% 1-year accuracy 22 / 75 met price target | 20%upside $312 | Outperform Reiterated | 28 Apr 2025 |
TD Securities Yaron Werber 50% 1-year accuracy 7 / 14 met price target | 29%upside $334 | Buy Reiterated | 24 Apr 2025 |
JP Morgan Jessica Fye 55% 1-year accuracy 21 / 38 met price target | 22%upside $317 | Overweight Maintained | 21 Apr 2025 |
RBC Capital Greg Renza 100% 1-year accuracy 1 / 1 met price target | 20%upside $312 | Outperform Initiated | 7 Apr 2025 |
Macquarie Tony Ren 0% 1-year accuracy 0 / 1 met price target | 20%upside $313 | Outperform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 5 articles about ONC published over the past 30 days
Neutral
Business Wire
1 day ago
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR pe.
Neutral
Investors Business Daily
6 days ago
Will This Cancer Stock Buck Trump's Tariff Onslaught As It Nears Buy Point, Earnings?
BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.
Neutral
Business Wire
1 week ago
BeiGene to Announce First Quarter 2025 Financial Results on May 7
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investo.
Negative
Benzinga
3 weeks ago
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit
BeiGene Ltd ONC on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.
Neutral
Business Wire
3 weeks ago
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre.
Neutral
Business Wire
1 month ago
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell l.
Positive
Benzinga
1 month ago
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
On Tuesday, BeiGene Ltd ONC announced FDA approval for Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).
Neutral
Business Wire
1 month ago
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). “The approval of TEVI.
Positive
Seeking Alpha
2 months ago
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with a 78% and 55% increase, positioning BeiGene for profitability. BeiGene announced a name change to BeOne Medicines, transitioning from historical losses to profitability, and potentially attracting new buyers.
Neutral
24/7 Wall Street
2 months ago
The Billionaire Baker Brothers Just Made This Big Biotech Stock Move
If you're interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.
Charts implemented using Lightweight Charts™